球囊扩张式瓣膜Sapien-3与Myval早期临床及血流动力学匹配比较
本研究基于欧洲九中心连续真实世界症状性重度主动脉瓣狭窄患者,经匹配比较Sapien-3与Myval球囊扩张式经导管心脏瓣膜的早期结局。匹配后各103对,两组手术成功率、30天死亡率、临床有效性和早期安全性相当,Myval组新永久起搏器需求更低(5.8% vs 15.5%,p=0.020),Sapien-3组平均跨瓣压差更高(p<0.001),≥中度主动脉瓣反流无显著差异。
要点
- 匹配后Myval组新永久起搏器植入率显著低于Sapien-3组(5.8% vs 15.5%,p=0.020)。
- 两组手术成功率、30天死亡率、临床有效性和早期安全性无显著差异。
- Sapien-3组术后平均跨瓣压差显著高于Myval组(p<0.001),≥中度主动脉瓣反流无显著差异。
核心结论
- Myval球囊扩张式瓣膜安全性良好,永久起搏器植入率低,残余压差和瓣周漏率经盲法超声评估令人满意。
研究设计与样本
- 研究为欧洲九中心连续真实世界患者的匹配比较,纳入2018年6月后接受Sapien-3或Myval治疗的 symptomatic severe aortic stenosis 患者。
- 共纳入416例(Sapien-3组286例,68.7%;Myval组130例,31.3%),匹配后比较103对。
- 匹配变量包括年龄、体表面积、STS风险评分、左心室功能、平均跨瓣压差、经股动脉入路、主动脉瓣钙化、主动脉瓣环平均直径、面积和偏心指数。
- 早期临床结局前瞻性收集,30天超声心动图进行盲法分析。
主要发现
- 手术成功率:Sapien-3组94.2%,Myval组93.2%(p=0.219)。
- 30天死亡率:Sapien-3组2.9%,Myval组0.97%(p=0.625)。
- 临床有效性:Sapien-3组12.6%,Myval组4.9%(p=0.057);早期安全性:Sapien-3组12.6%,Myval组4.9%(p=0.096)。
- 新永久起搏器植入:Sapien-3组15.5%,Myval组5.8%(p=0.020)。
- ≥中度主动脉瓣反流:Sapien-3组1%,Myval组0%(p=0.314);平均跨瓣压差Sapien-3组高于Myval组(p<0.001)。
临床怎么用
- 在匹配的真实世界人群中,Myval瓣膜可考虑作为球囊扩张式瓣膜的替代选择,尤其关注起搏器风险时。
- Sapien-3组术后平均跨瓣压差较高,需关注血流动力学表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The balloon-expandable Sapien-3 valve demonstrated superior results in terms of residual aortic regurgitation when compared with self-expandable devices. We aimed to compare for the first-time early outcomes of Sapien-3 transcatheter heart valve (THV) with the balloon-expandable Myval device. METHODS: Consecutive real-world patients from nine European institutions with symptomatic severe aortic stenosis treated either with Sapien-3 or Myval THV devices after June 2018 were compared. Early clinical outcomes were prospectively gathered and blinded analysis of 30-day echocardiography was conducted. Matching for the following variables was performed: age, body surface area, Society of Thoracic Surgeons risk score, left ventricular function, mean gradient, transfemoral approach, aortic valvular calcium, aortic annulus mean diameter, area and eccentricity index. RESULTS: A total of 416 patients treated either with the Sapien-3 (n=286, 68.7%) or with Myval THV (n=130, 31.3%) were included and 103 pairs compared after matching. Baseline characteristics were similar. Procedural success rate (Sapien-3: 94.2%; Myval: 93.2%, p=0.219), 30-day mortality (Sapien-3: 2.9%; Myval: 0.97%, p=0.625), clinical efficacy (12.6 vs 4.9%, p=0.057) and early safety (12.6 vs 4.9%, p=0.096) were comparable. There was a lower need for new permanent pacemaker (15.5 vs 5.8% p=0.020) with Myval. No significant differences were found in terms of ≥moderate aortic regurgitation (1% for Sapien-3, 0% for Myval, p=0.314), but mean gradients were higher following Sapien-3 than after Myval (p<0.001). CONCLUSIONS: The new Myval balloon-expandable THV was favourable in terms of safety, with low rate of permanent pacemaker and with favourable residual gradients and paravalvular leak rate according to blinded echocardiographic analysis.
引用
- Delgado-Arana JR, Gordillo-Monge MX, Halim J, et al. Early clinical and haemodynamic matched comparison of balloon-expandable valves. Heart. 2021. PMID: 34285104. doi:10.1136/heartjnl-2021-319349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。